Clovis Oncology (CLVS) PT Raised to $45 at Stifel Amid De-Risking Events

September 21, 2016 7:30 AM EDT Send to a Friend
Stifel analyst Thomas Shrader reiterated a Buy rating and raised his price target on Clovis Oncology (NASDAQ: CLVS) to $45.00 ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login